Sentinels / Actor desk
National Reimbursement Drug List Of China
organization · Registry status: unverified
c6e663d6-e623-5d4c-846c-185840d1b3ef
Evidence, not intent.
Public-source event mentions and stored signals. Adjacency does not establish causation, coordination, or an actor's position.
No claim of complete coverage or live monitoring.
Observation window
UTC dates, inclusive · maximum 90 days. Applies to events and anomalies only.
Recent observations / timeline
The source record
26 distinct events shown, newest first. Headlines may be generated summaries; inspect the source before repeating a claim.
AstraZeneca (AZN) Q3 2026 Earnings Call Transcript | The Motley Fool
Lilly Raises 2026 Revenue Outlook as Mounjaro, Zepbound Sales Rise | EconoTimes
Eli Lilly (LLY) Q3 2026 Earnings Call Transcript | The Motley Fool
Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio
GSK (GSK) Q3 2026 Earnings Call Transcript | The Motley Fool
Eli Lilly (NYSE: LLY) Earnings On October 29 Put A $1.135 Trillion Bet On Two Blockbuster Drugs To The Test
The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine - Australian Bloggers
Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO
Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO
Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO – Thailand Business News
The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine – Thailand Business News
Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO
The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine
Phase II Results of Sacituzumab Tirumotecan (sac-TMT) plus Pembrolizumab in Advanced Urothelial Carcinoma Presented at 2026 ESMO - Australian Bloggers
Phase II Results of Sacituzumab Tirumotecan (sac-TMT) plus Pembrolizumab in Advanced Urothelial Carcinoma Presented at 2026 ESMO – Thailand Business News
Phase II Results of Sacituzumab Tirumotecan (sac-TMT) plus Pembrolizumab in Advanced Urothelial Carcinoma Presented at 2026 ESMO
Kelun-Biotech to Present Multiple Study Results at ESMO 2026
Hiteck Licenses Investigational Next-Generation NGF Eye Drop HT006.2.2 to Visara for Neurotrophic Keratitis Outside Greater China
Kelun-Biotech to Present Multiple Study Results at ESMO 2026
finanzen.ch: Innovent Biologics, China National Reimbursement Drug List (medical, wb 1331 health technologies)
Innovent Announces Phase 3 RESTORE-3 Study of SYCUME® (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye Disease - Thailand Business News
Innovent Announces Phase 3 RESTORE-3 Study of SYCUME® (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye Disease
Innovent Announces Phase 3 RESTORE-3 Study of SYCUME® (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye Disease
Innovent Announces Phase 3 RESTORE-3 Study of SYCUME® (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye Disease
Everest Medicines Announces the Acceptance and Priority Review of VELSIPITY(R) Manufacturing Localiz
Everest Medicines Announces the Acceptance and Priority Review of VELSIPITY(R)
Signals to inspect
Anomalies
Latest 10 in the selected window (up to 10). Detector output, not verified conclusions.
Volume spike: 2 events in window (2.0x baseline of 1.0 expected)
Volume spike: 3 events in window (3.0x baseline of 1.0 expected)
New connection: 8 previously unseen co-actor(s) detected (known network: 22)
New connection: 3 previously unseen co-actor(s) detected (known network: 20)
Volume spike: 4 events in window (4.0x baseline of 1.0 expected)
New connection: 1 previously unseen co-actor(s) detected (known network: 19)
Volume spike: 5 events in window (5.0x baseline of 1.0 expected)
Coordination signal: co-actor 04f751dc-1cbc-5b47-b3b1-5953f3bff2e1 appeared in 7 of 8 window events (88%)
Volume spike: 6 events in window (6.0x baseline of 1.0 expected)
Narrative context
Unresolved threads
Latest 20 at most, across all dates. Stored narratives require human review.
No unresolved threads recorded.
Stored connections
Relationships
Up to 50 records ordered by evidence count, across all dates. Co-mentions indicate association in source material, not affiliation or coordination.
- Chinese National Medical Products Administration→ co mention →National Reimbursement Drug List Of China65 evidence records
- National Reimbursement Drug List Of China→ co mention →United States Senate63 evidence records
- American Society Of Pediatric Hematology Oncology→ co mention →National Reimbursement Drug List Of China34 evidence records
- Terms Of Service→ co mention →National Reimbursement Drug List Of China33 evidence records
- Drug Enforcement Administration→ co mention →National Reimbursement Drug List Of China26 evidence records
- Society For Tropical Ecology→ co mention →National Reimbursement Drug List Of China24 evidence records
- Pfizer→ co mention →National Reimbursement Drug List Of China18 evidence records
- National Reimbursement Drug List Of China→ co mention →Securities and Exchange Commission17 evidence records
- Astrazeneca→ co mention →National Reimbursement Drug List Of China17 evidence records
- National Reimbursement Drug List Of China→ co mention →Dana-Farber Cancer Institute16 evidence records
- Stock Exchange Of Hong Kong Limited Hkex→ co mention →National Reimbursement Drug List Of China16 evidence records
- National Reimbursement Drug List Of China→ co mention →Eli Lilly15 evidence records
- National Reimbursement Drug List Of China→ co mention →Given Ascentage Pharma Group International14 evidence records
- Prnewswire Telix Pharmaceuticals Limited→ co mention →National Reimbursement Drug List Of China14 evidence records
- Eastern Michigan University→ co mention →National Reimbursement Drug List Of China13 evidence records
- National Cancer Institute Of Kenya Ncikenya→ co mention →National Reimbursement Drug List Of China13 evidence records
- National Reimbursement Drug List Of China→ co mention →Ascentage Pharma Lisaftoclax13 evidence records
- Amarillo Biosciences→ co mention →National Reimbursement Drug List Of China12 evidence records
- National Reimbursement Drug List Of China→ co mention →European Union12 evidence records
- Stella Yaromy→ co mention →National Reimbursement Drug List Of China11 evidence records
- Yanni Jason→ co mention →National Reimbursement Drug List Of China11 evidence records
- American Associated Of Cancer Research→ co mention →National Reimbursement Drug List Of China11 evidence records
- National Reimbursement Drug List Of China→ co mention →Taurox Pr Team9 evidence records
- National Reimbursement Drug List Of China→ co mention →Team Ireland9 evidence records
- Li Zhibo→ co mention →National Reimbursement Drug List Of China9 evidence records
- Merck Sharp Dohme→ co mention →National Reimbursement Drug List Of China8 evidence records
- Prnewswire Sichuan Kelun→ co mention →National Reimbursement Drug List Of China8 evidence records
- Arab Population Monitoring Committee→ co mention →National Reimbursement Drug List Of China7 evidence records
- Nasdaq→ co mention →National Reimbursement Drug List Of China6 evidence records
- Red Blood Cell Disease Anemia Group→ co mention →National Reimbursement Drug List Of China6 evidence records
- Sun Pharmaceuticals On→ co mention →National Reimbursement Drug List Of China6 evidence records
- Zuellig Pharma→ co mention →National Reimbursement Drug List Of China6 evidence records
- National Reimbursement Drug List Of China→ co mention →Dave Ricks6 evidence records
- Blind Independent Pathology Review Committee→ co mention →National Reimbursement Drug List Of China6 evidence records
- French Medical Association→ co mention →National Reimbursement Drug List Of China6 evidence records
- Keck School Of Medicine→ co mention →National Reimbursement Drug List Of China6 evidence records
- National Reimbursement Drug List Of China→ co mention →French Society Of Dermatology6 evidence records
- Seojun Yang→ co mention →National Reimbursement Drug List Of China6 evidence records
- International Planned Parenthood Federation→ co mention →National Reimbursement Drug List Of China6 evidence records
- Indore Pharma Lab→ co mention →National Reimbursement Drug List Of China5 evidence records
- Boehringer Ingelheim→ co mention →National Reimbursement Drug List Of China5 evidence records
- American Educational Research Association Annual Meeting→ co mention →National Reimbursement Drug List Of China5 evidence records
- National Reimbursement Drug List Of China→ co mention →Quarter For Gilead Sciences5 evidence records
- Georgia Society Of Oncology→ co mention →National Reimbursement Drug List Of China5 evidence records
- Amgen→ co mention →National Reimbursement Drug List Of China5 evidence records
- National Reimbursement Drug List Of China→ co mention →National Student Clearinghouse Research Center5 evidence records
- Sean Levert→ co mention →National Reimbursement Drug List Of China5 evidence records
- Stephanie Fairyington→ co mention →National Reimbursement Drug List Of China5 evidence records
- China Medical System Holdings Limited The Group→ co mention →National Reimbursement Drug List Of China5 evidence records
- European Medicines Agency Clinical Trial Application→ co mention →National Reimbursement Drug List Of China5 evidence records
Ask this desk
Desk analyst
Read-only questions about National Reimbursement Drug List Of China's stored record. Answers cite only records retrieved for that turn; a citation chip opens the existing inspection view. Absence of matches is not evidence of inactivity.
Operator sign-in is required. Sign in